Relx (LON:REL) PT Raised to GBX 2,540 at Barclays

Relx (LON:REL) had its price objective upped by Barclays from GBX 2,500 ($32.66) to GBX 2,540 ($33.19) in a report issued on Friday, Price Targets.com reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 13.09% from the company’s previous close.

A number of other research analysts also recently issued reports on the company. UBS Group set a GBX 2,135 ($27.89) price objective on Relx in a research note on Thursday. restated a “buy” rating and issued a GBX 2,300 ($30.05) price target on shares of Relx in a research note on Monday, July 5th. Credit Suisse Group set a GBX 2,500 ($32.66) price target on Relx in a research note on Thursday, October 7th. Citigroup restated a “buy” rating and issued a GBX 2,300 ($30.05) price target on shares of Relx in a research note on Monday, July 5th. Finally, Morgan Stanley reiterated a “buy” rating and set a GBX 2,100 ($27.44) target price on shares of Relx in a research report on Wednesday, June 30th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of GBX 2,281.64 ($29.81).

Shares of LON:REL opened at GBX 2,246 ($29.34) on Friday. The stock has a 50 day moving average of GBX 2,176.49 and a 200 day moving average of GBX 2,022.04. The company has a market cap of £43.45 billion and a PE ratio of 32.46. The company has a current ratio of 0.53, a quick ratio of 0.46 and a debt-to-equity ratio of 268.46. Relx has a 12-month low of GBX 1,484.90 ($19.40) and a 12-month high of GBX 2,274 ($29.71).

In other Relx news, insider Paul Walker bought 16,000 shares of Relx stock in a transaction on Friday, September 24th. The shares were acquired at an average price of GBX 2,202 ($28.77) per share, for a total transaction of £352,320 ($460,308.34).

Relx Company Profile

RELX PLC provides information-based analytics and decision tools for professional and business customers in North America, Europe, and internationally. It operates through four segments: Scientific, Technical & Medical; Risk; Legal; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics that help institutions and professionals to progress in science and advance healthcare.

Recommended Story: How do buyers and sellers choose a strike price?

Analyst Recommendations for Relx (LON:REL)

Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.